Interleukin Genetics reported an increase in revenues and a slightly decreased overall loss for the second quarter of 2016.
For the quarter (end-June 30), the company reported revenues of $590,000, up from $376,000 from the same quarter in 2015, according to the company. Net loss for the first quarter was $2.1 million, down from $2.2 million in the same period of 2015.
The company produces the PerioPredict genetic test.
